Literature DB >> 22950955

Drug treatment of metabolic syndrome.

Velimir Altabas1.   

Abstract

The metabolic syndrome is a constellation of risk factors for cardiovascular diseases including: abdominal obesity, a decreased ability to metabolize glucose (increased blood glucose levels and/or presence of insulin resistance), dyslipidemia, and hypertension. Patients who have developed this syndrome have been shown to be at an increased risk of developing cardiovascular disease and/or type 2 diabetes. Genetic factors and the environment both are important in the development of the metabolic syndrome, influencing all single components of this syndrome. The goals of therapy are to treat the underlying cause of the syndrome, to reduce morbidity, and to prevent complications, including premature death. Lifestyle modification is the preferred first-step treatment of the metabolic syndrome. There is no single effective drug treatment affecting all components of the syndrome equally known yet. However, each component of metabolic syndrome has independent goals to be achieved, so miscellaneous types of drugs are used in the treatment of this syndrome, including weight losing drugs, antidiabetics, antihypertensives, antilipemic and anticlothing drugs etc. This article provides a brief insight into contemporary drug treatment of components the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22950955     DOI: 10.2174/1574884711308030009

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  3 in total

Review 1.  An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches.

Authors:  Mizael C Araújo; Suzany H S Soczek; Jaqueline P Pontes; Leonardo A C Marques; Gabriela S Santos; Gisele Simão; Laryssa R Bueno; Daniele Maria-Ferreira; Marcelo N Muscará; Elizabeth S Fernandes
Journal:  Cells       Date:  2022-04-11       Impact factor: 7.666

2.  Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome.

Authors:  Luca Cannizzaro; Giuseppe Rossoni; Federica Savi; Alessandra Altomare; Cristina Marinello; Thammakorn Saethang; Marina Carini; D Michael Payne; Trairak Pisitkun; Giancarlo Aldini; Asada Leelahavanichkul
Journal:  Nutr Metab (Lond)       Date:  2017-01-13       Impact factor: 4.169

3.  Lactobacillus plantarum S9 alleviates lipid profile, insulin resistance, and inflammation in high-fat diet-induced metabolic syndrome rats.

Authors:  Lei Zhao; Yunjiao Shen; Yunlong Wang; Lei Wang; Lin Zhang; Zijian Zhao; Shengyu Li
Journal:  Sci Rep       Date:  2022-09-15       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.